XT
CBIO

XTX Topco’s Crescent Biopharma CBIO Stock Holding History

XTX Topco’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-642
Closed -$16K – 2640
2024
Q4 		$16K Buy
642
+393
+158% +$10.7K ﹤0.01% 2080
2024
Q3 		$4.21K Buy
+249
New +$5.22K ﹤0.01% 1984
2024
Q1 		– Sell
-111
Closed -$26.2K – 2017
2023
Q4 		$26.2K Sell
111
-216
-66% -$33.6K 0.01% 1329
2023
Q3 		$49.1K Buy
327
+27
+9% +$4.26K 0.01% 1282
2023
Q2 		$52.2K Buy
+300
New +$50.3K 0.01% 1234
2023
Q1 		– Sell
-636
Closed -$193K – 1422
2022
Q4 		$193K Buy
+636
New +$93.8K 0.04% 860
2021
Q3 		– Sell
-590
Closed -$137K – 812
2021
Q2 		$137K Buy
+590
New +$150K 0.05% 620

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $1.94B AUM 444.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $8.2B AUM 40.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return